722.F ANTENGENE CORP. DL-0001
- Market cap
- EUR 183M
- P/E
- 30.0x
- P/B
- 1.50x
- ROE
- -37.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 722.F undervalued?
Graham number722.F trades 41.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ANTENGENE CORP. DL-0001 fundamental analysis
No fundamental analysis for ANTENGENE CORP. DL-0001 yet.
ANTENGENE CORP. DL-0001 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage …
Full company profileANTENGENE CORP. DL-0001 financial statements
ANTENGENE CORP. DL-0001 annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 28.8M | 160M | 67.3M | 92.0M | 105M |
| Gross Profit | 24.2M | 132M | 55.0M | 75.3M | 88.0M |
| Operating Income | -594M | -869M | -662M | -348M | -211M |
| EBITDA | - | -573M | -550M | -292M | -213M |
| Net Income | -656M | -601M | -581M | -319M | -239M |
| EPS | -1.05 | -0.98 | -0.95 | -0.52 | -0.39 |
| Balance Sheet | |||||
| Total Assets | 2.56B | 2.14B | 1.62B | 1.34B | 1.26B |
| Total Liabilities | 163M | 429M | 471M | 494M | 615M |
| Shareholders' Equity | 2.39B | 1.71B | 1.15B | 851M | 642M |
| Cash & Short-term Investments | 2.27B | 1.78B | 1.18B | 885M | 718M |
| Cash Flow | |||||
| Operating Cash Flow | -558M | -572M | -666M | -322M | -128M |
| Capital Expenditure | 70.3M | 99.4M | 113M | 60.6M | 51.4M |
| Free Cash Flow | -628M | -672M | -779M | -383M | -179M |
| Ratios | |||||
| ROE | -27.4% | -35.1% | -50.7% | -37.5% | -37.2% |
| ROA | -25.6% | -28.1% | -35.9% | -23.7% | -19.0% |
| Net Profit Margin | -2,278.6% | -375.6% | -863.5% | -347.2% | -227.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ANTENGENE CORP. DL-0001 dividends
ANTENGENE CORP. DL-0001 has not paid dividends in the last 5 fiscal years.
Who owns ANTENGENE CORP. DL-0001
- Insiders 37.22%
- Institutions 7.81%
- Public & others 54.97%
- Shares outstanding 611M
- Free float 356M
ANTENGENE CORP. DL-0001 company profile
- Company name
- ANTENGENE CORP. DL-0001
- Ticker
- 722.F
- ISIN
- KYG039571008
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 122
- Fiscal year end
- December
- Address
- Zhongshan SOHO Plaza, Shanghai, China, 200051
- Phone
- 86 21 2356 6665
- Website
- antengene.com
About ANTENGENE CORP. DL-0001
Antengene Corporation Limited, a clinical-stage APAC biopharmaceutical company, develops novel oncology therapies in Greater China and internationally. The company's commercialized assets include ATG-010 (selinexor), an oral SINE compound for the treatment of various hematological malignancies and solid tumors comprising relapsed/refractory multiple myeloma (rrMM), relapsed/refractory diffuse large B-cell lymphoma, and multiple myeloma (MM) in adult patients. Its late-stage products candidates comprise ATG-008 (onatasertib), an mTOR inhibitor for the treatment of cervical cancer and other advanced solid tumors. It also develops other clinical stage assets, such as ATG-022, an antibody-drug conjugate which is in Phase II for the treatment of patients with advanced or metastatic gastric cancer; ATG-031, an anti-CD24 monoclonal antibody, which is in Phase I for the treatment of advanced solid tumors; ATG-037, an CD73 inhibitor that is in Phase I for the treatment of locally advanced or metastatic solid tumors; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is I Phase I trial for the treatment of advanced/metastatic solid tumors and B-cell non Hodgkin lymphoma (B-NHL). In addition, the company's pre-clinical stage assets consist of ATG-042, an PRMT5-MTA inhibitor; ATG-201 a CD19 x CD3 T cell engager; ATG-102, a LILRB4 x CD3 T cell engager; ATG-106, a CDH6 x CD3 T cell engager; ATG-107, a FLT3 x CD3 T cell engager; and ATG-110, a LY6G6D x CD3 T cell engager. Further, the company develops AnTenGager, an 2+1 T cell engager platform which enables conditional T cell activation with reduced risk of cytokine release syndrome; and engages in the trading activities. Antengene Corporation Limited was founded in 2017 and is based in Shanghai, China.
ANTENGENE CORP. DL-0001 management
9- Dr. Jay Mei M.D., Ph.D.Founder, Chairman & CEO · born 1965
- Mr. Yiteng Liu M.Sc.Chief Operating Officer · born 1985
- Mr. Thomas Karalis B.Sc.Corporate VP & Head of Asia Pacific Region
- Ms. Rui GuoChief Business Officer
- Dr. Hou Bing Ph.D.Chief Scientific Officer & Executive Director · born 1984
- Ms. Shimin Sun M.D., M.P.H.Corporate VP and Head of Clinical Enabling Functions & Operational Excellence
- Dr. Dirk HoenemannVP and Head of Medical Affairs for APAC & Early Clinical Development
- Ms. Ying LiuJoint Company Secretary
- Ms. Chin Hei LamJoint Company Secretary